Product Description
Benzbromarone is a nonpurine xanthine oxidase inhibitor used for the treatment of gout, but never approved for use in the United States because of concerns over reports of acute liver injury and deaths with its use. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Benzbromarone)
Mechanisms of Action: URAT1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Brazil | Chile | China | Dominican Republic | Egypt | Hong Kong | Malaysia | Netherlands | Pakistan | Portugal | Singapore | Slovenia | Spain | Taiwan | Thailand | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Changzhou Kangpu Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Heart Failure|Ventricular Dysfunction, Left
Phase 3: Gout
Phase 2: Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ChiCTR2400081315 | N/A |
Not yet recruiting |
Unknown |
2025-10-31 |
|
| ChiCTR2200055197 | N/A |
Recruiting |
Gout |
2023-01-04 |
|
| ChiCTR2100055092 | N/A |
Not yet recruiting |
Gout |
2022-04-01 |
|
| ChiCTR1900023033 | N/A |
Recruiting |
Hypertrophy, Left Ventricular |
2021-12-31 |